These results, albeit limited to the cell lines we studied, support a model whereby cells carrying RAS mutations are latently present (that is, pre-exist) in WT CRC populations sensitive to EGFR blockade and rapidly expand under anti-EGFR drug pressure. This evidence concerns the gene EGFR and colorectal carcinoma.